Autorisation d’accès précoce refusée à la spécialité TEPEZZA (téprotumumab) dans l'indication « traitement des patients adultes atteints d’ophtalmopathie basedowienne modérée à sévère ».
See also
HAS opinions and decisions
26/02/2025
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
kQNZ1Z3u8y9Z6cKf
